CN Bio Innovations, an expert in developing human organ-on-a-chip platforms to test and develop therapeutics for liver diseases and infection, is pleased to announce the commencement of a research collaboration with Alnylam Pharmaceuticals. Research relevant to the advancement of Alnylam’s RNAi therapeutics will be performed using CN Bio’s human liver-on-a-chip platform, LiverChip.
This deal follows announcements earlier in 2015 of collaborations with Benitec BioPharma, Isis Pharmaceuticals and a number of global pharmaceutical companies, demonstrating strong interest from the industry in CN Bio’s LiverChip platform and Hepatitis B disease model Quantum-B®.
Dr Emma Sceats, CN Bio’s Chief Operating Officer, said “After years of hype surrounding organ-on-chip technologies the reality in 2015 is that a highly complex organ like the liver can be built in the laboratory and used to advance our understanding of various disease and infections. We are excited to be applying these technologies in programs with several pharmaceutical partners and expect new insights into novel therapeutic approaches will arise from these collaborations.”
Read the full press release here.